Press releases
- Press releases
- Browse
Press releases
Studies Show Miraxion Modulated Cellular Function and Demonstrated Neuroprotective Effects in Parkinson's Disease Models More
Amarin has licensed to Multicell exclusive, worldwide rights of LAX-202 for the treatment of fatigue in patients suffering from multiple sclerosis. More
BioXell S.p.A. and Lay Line Genomics S.p.A. (LLG) today announced an exclusive, worldwide license agreement for the development of MNAC13, a novel humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor More
Related Reports
Market Research Reports provided by reports.iptechex.com
Sep 2011 - 97 pages - $3,500
Feb 2011 - 75 pages - $1,000
Jun 2006 - 1068 pages - $2,495
Aug 2010 - 76 pages - $1,500
Nov 2011 - 61 pages - $3,800
Oct 2010 - 53 pages - $1,000
Feb 2011 - 209 pages - $3,500
Jan 2010 - $75
Mar 2011 - 6 pages - $500
Dec 2010 - 68 pages - $1,000
Your selection
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Alzheimer's disease
- Amyotrophic Lateral Sclerosis (Lou Gehri
- Creutzfeldt-Jakob disease
- Dementia
- Multiple sclerosis
- Parkinson's disease
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us